Review: Variability of host—pathogen interaction

Abstract

The course of every infection is different. The same pathogen can lead to subclinical, mild, severe or lethal infections in individuals. But is this just chance or determined by individual differences — on the side of the host as well as on the side of the pathogen? If so, we might need to consider these variations for treatment decisions. Indeed, we now understand that genetic polymorphisms and health status represent inborn and acquired risk factors. Similarly, pathogens impress with an increasing number of already identified virulence factors and host response modifiers. The emerging, more complex, view of the factors determining course and outcome of infections promises to enable more tailored and thus, hopefully, more effective treatment decisions.

Keywords

Host—pathogen interaction Infection

References

Boxer L. , Dale DC Neutropenia: causes and consequences. Semin Hematol 2002; 39: 75—81.

Roos D. , Law SK Hematologically important mutations: leukocyte adhesion deficiency. Blood Cells Mol Dis 2001; 27: 1000—1004.

Jonsson G. , Truedsson L. , Sturfelt G. , Oxelius VA , Braconier JH , Sjoholm AG Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 2005; 84: 23—34.

Heyworth PG , Cross AR , Curnutte JT Chronic granulomatous disease. Curr Opin Immunol 2003; 15: 578—584.

Alverdy JC , Laughlin RS , Wu L. Influence of the critically ill state on host—pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003; 31: 598—607.

Marsh CB , Wewers MD The pathogenesis of sepsis. Factors that modulate the response to Gram-negative bacterial infection. Clin Chest Med 1996; 17: 183—197.

Steere AC , Coburn J. , Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113: 1093—1101.

Campbell LA , Kuo CC

Chlamydia pneumoniae — an infectious risk factor for atherosclerosis?

Nat Rev Microbiol 2004; 2: 23—32.

MacDowell AL , Bacharier LB Infectious triggers of asthma. Immunol Allergy Clin North Am 2005; 25: 45—66.

10.

Hogan RJ , Mathews SA , Mukhopadhyay S. , Summersgill JT , Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004; 72: 1843—1855.

11.

Sorensen TI , Nielsen GG , Andersen PK , Teasdale TW Genetic and environmental influences on premature death in adult adoptees . N Engl J Med 1988; 318: 727—732.

12.

Geraghty DE , Fortelny S. , Guthrie B. et al. Data acquisition, data storage, and data presentation in a modern genetics laboratory. Rev Immunogenet 2000; 2: 532—540.

13.

Sarvetnick N. , Fox HS Interferon-gamma and the sexual dimorphism of autoimmunity. Mol Biol Med 1990; 7: 323—331.

14.

Offner PJ , Moore EE , Biffl WL Male gender is a risk factor for major infections after surgery. Arch Surg 1999; 134: 935—938, discussion 938—940.

15.

Ono S. , Tsujimoto H. , Hiraki S. , Takahata R. , Kinoshita M. , Mochizuki H. Sex differences in cytokine production and surface antigen expression of peripheral blood mononuclear cells after surgery. Am J Surg 2005; 190: 439—444.

16.

Bone RC , Balk RA , Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644—1655.

17.

Aulock SV , Deininger S. , Draing C. , Gueinzius K. , Dehus O. , Hermann C. Gender difference in cytokine secretion on immune stimulation with LPS and LTA. J Interferon Cytokine Res 2006; 26: 887—892.

18.

Geraghty DE , Daza R. , Williams LM , Vu Q. , Ishitani A. Genetics of the immune response: identifying immune variation within the MHC and throughout the genome. Immunol Rev 2002; 190: 69—85.

19.

Winchester R. , Dwyer E. MHC and autoimmune diseases: susceptibility to rheumatoid arthritis associated with a hydrophobic strip of alpha helix encoded by several MHC alleles. Immunol Ser 1991; 55: 203—219.

20.

Lepage V. , Lamm LU , Charron D. Molecular aspects of HLA class II and some autoimmune diseases. Eur J Immunogenet 1993; 20: 153—164.

21.

Ovsyannikova IG , Jacobson RM , Poland GA Variation in vaccine response in normal populations . Pharmacogenomics 2004; 5: 417—427.

22.

Singh N. , Agrawal S. , Rastogi AK Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis 1997; 3: 41—49.

23.

Kacprzak-Bergman I. , Nowakowska B. Influence of genetic factors on the susceptibility to HBV infection, its clinical pictures, and responsiveness to HBV vaccination . Arch Immunol Ther Exp (Warsz) 2005; 53: 139—142.

24.

Hildesheim A. , Wang SS Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89: 229—240.

25.

Kaslow RA , Dorak T. , Tang JJ Influence of host genetic variation on susceptibility to HIV type 1 infection . J Infect Dis 2005; 191 (Suppl 1): S68—S77.

26.

Stephens HA HIV-1 diversity versus HLA class I polymorphism . Trends Immunol 2005; 26: 41—47.

27.

Guerau-de-Arellano M. , Huber BT Development of autoimmunity in Lyme arthritis . Curr Opin Rheumatol 2002; 14: 388—393.

28.

Steere AC , Dwyer E. , Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990; 323: 219—223.

29.

Hubacek JA , Rothe G. , Pit'ha J. et al. C(—260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99: 3218—3220.

30.

Unkelbach K. , Gardemann A. , Kostrzewa M. , Philipp M. , Tillmanns H. , Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19: 932—938.

31.

Baldini M. , Lohman IC , Halonen M. , Erickson RP , Holt PG , Martinez FD A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E . Am J Respir Cell Mol Biol 1999; 20: 976—983.

32.

von Aulock S. , Rupp J. , Gueinzius K. , Maass M. , Hermann C. Critical investigation of the CD14 promoter polymorphism: lack of a role for in vitro cytokine response and membrane CD14 expression. Clin Diagn Lab Immunol 2005; 12: 1254—1256.

33.

Koch W. , Kastrati A. , Mehilli J. , von Beckerath N. , Schomig A. CD14 gene —159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. Am Heart J 2002; 143: 971—976.

34.

Ito D. , Murata M. , Tanahashi N. et al. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 2000; 31: 2661—2664.

35.

Morange PE , Tiret L. , Saut N. et al. TLR4/Asp299Gly, CD14/C—260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12: 1041—1049.

36.

Amar J. , Ruidavets JB , Bal dit Sollier C. et al. CD14 C(—260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. J Hypertens 2004 ; 22: 1523—1528.

37.

Longobardo MT , Cefalu AB , Pezzino F. et al. The C(—260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction. Clin Exp Med 2003; 3: 161—165.

38.

Zee RY , Lindpaintner K. , Struk B. , Hennekens CH , Ridker PM A prospective evaluation of the CD14 C(—260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001; 154: 699—702.

39.

Arroyo-Espliguero R. , El-Sharnouby K. , Vazquez-Rey E. , Kalidas K. , Jeffery S. , Kaski JC CD14 C(—260)T promoter polymorphism and prevalence of acute coronary syndromes. Int J Cardiol 2005; 98: 307—312.

40.

Kruger S. , Graf J. , Merx MW et al. CD14 gene —260 C/T polymorphism is associated with chronic heart failure. Eur J Intern Med 2005; 16: 345—347.

41.

Griga T. , Wilkens C. , Schmiegel W. et al. Association between the promoter polymorphism T/C at position —159 of the CD14 gene and anti-inflammatory therapy in patients with inflammatory bowel disease. Eur J Med Res 2005; 10: 183—186.

42.

Griga T. , Klein W. , Epplen JT , Hebler U. , Stachon A. , May B. CD14 expression on monocytes and soluble CD14 plasma levels in correlation to the promotor polymorphism of the endotoxin receptor CD14 gene in patients with inactive Crohn's disease. Hepatogastroenterology 2005; 52: 808—811.

43.

Klausz G. , Molnar T. , Nagy F. et al. Polymorphism of the heat-shock protein gene Hsp70-2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of Crohn's disease . Scand J Gastroenterol 2005; 40: 1197—1204.

44.

Heesen M. , Blomeke B. , Schluter B. , Heussen N. , Rossaint R. , Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med 2001; 27: 1770—1775.

45.

Eng HL , Wang CH , Chen CH , Chou MH , Cheng CT , Lin TM A CD14 promoter polymorphism is associated with CD14 expression and Chlamydia-stimulated TNF alpha production. Genes Immun 2004; 5: 426—430.

46.

Smirnova I. , Poltorak A. , Chan EK , McBride C. , Beutler B. Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4). Genome Biol 2000; 1: RESEARCH002.

47.

Akashi S. , Saitoh S. , Wakabayashi Y. et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4—MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198: 1035—1042.

48.

Miyake K. Innate recognition of lipopolysaccharide by CD14 and Toll-like receptor 4—MD-2: unique roles for MD-2. Int Immunopharmacol 2003; 3: 119—128.

49.

Akashi S. , Ogata H. , Kirikae F. et al. Regulatory roles for CD14 and phosphatidylinositol in the signaling via Toll-like receptor 4—MD-2. Biochem Biophys Res Commun 2000; 268: 172—177.

50.

Arbour NC , Lorenz E. , Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187—191.

51.

Rallabhandi P. , Bell J. , Boukhvalova MS et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006; 177: 322—332.

52.

von Aulock S. , Schroder NW , Gueinzius K. et al. Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938—943.

53.

van der Graaf CA , Netea MG , Drenth IP , te Morsche RH , van der Meer JW , Kullberg BJ Candida-specific interferon-gamma deficiency and Toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med 2003; 61: 365—369.

54.

Van der Graaf CA , Netea MG , Morre SA et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006; 17: 29—34.

55.

Agnese DM , Calvano JE , Hahm SJ et al. Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis 2002; 186: 1522—1525.

56.

Lorenz E. , Mira JP , Frees KL , Schwartz DA Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162: 1028—1032.

57.

Feterowski C. , Emmanuilidis K. , Miethke T. et al. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003; 109: 426—431.

58.

Child NJ , Yang IA , Pulletz MC et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003; 31: 652—653.

59.

Read RC , Pullin J. , Gregory S. et al. A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184: 640—642.

60.

Allen A. , Obaro S. , Bojang K. et al. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 2003; 22: 1018—1019.

61.

Tal G. , Mandelberg A. , Dalal I. et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189: 2057—2063.

62.

Folwaczny M. , Glas J. , Torok HP , Limbersky O. , Folwaczny C. Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease. Clin Exp Immunol 2004 ; 135: 330—335.

63.

Schroder NW , Meister D. , Wolff V. et al. Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 gene. Genes Immun 2005; 6: 448—451.

64.

Kilding R. , Akil M. , Till S. et al. A biologically important single nucleotide polymorphism within the Toll-like receptor-4 gene is not associated with rheumatoid arthritis . Clin Exp Rheumatol 2003; 21: 340—342.

65.

Sanchez E. , Orozco G. , Lopez-Nevot MA , Jimenez-Alonso J. , Martin J. Polymorphisms of Toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004; 63: 54—57.

66.

Reindl M. , Lutterotti A. , Ingram J. et al. Mutations in the gene for Toll-like receptor 4 and multiple sclerosis. Tissue Antigens 2003; 61: 85—88.

67.

Kroner A. , Vogel F. , Kolb-Maurer A. et al. Impact of the Asp299Gly polymorphism in the Toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis. J Neuroimmunol 2005; 165: 161—165.

68.

Raby BA , Klimecki WT , Laprise C. et al. Polymorphisms in Toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. Am J Respir Crit Care Med 2002; 166: 1449—1456.

69.

Yang IA , Barton SJ , Rorke S. et al. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics . Genes Immun 2004; 5: 41—45.

70.

Noguchi E. , Nishimura F. , Fukai H. et al. An association study of asthma and total serum immunoglobulin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 2004; 34: 177—183.

71.

Franchimont D. , Vermeire S. , El Housni H. et al. Deficient host—bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis . Gut 2005; 54: 308.

72.

Torok H. , Glas J. , Tonenchi L. , Mussack T. , Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004 ; 112: 85—91.

73.

Oostenbrug LE , Drenth JP , de Jong DJ et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 567—575.

74.

Lorenz E. , Hallman M. , Marttila R. , Haataja R. , Schwartz DA Association between the Asp299Gly polymorphisms in the Toll-like receptor 4 and premature births in the Finnish population. Pediatr Res 2002; 52: 373—376.

75.

Kiechl S. , Lorenz E. , Reindl M. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185—192.

76.

Ameziane N. , Beillat T. , Verpillat P. et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61—e64.

77.

Balistreri CR , Candore G. , Colonna-Romano G. et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004; 292: 2339—2340.

78.

Yang IA , Holloway JW , Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis . Atherosclerosis 2003; 170: 187—190.

79.

Reismann P. , Lichy C. , Rudofsky G. et al. Lack of association between polymorphisms of the Toll-like receptor 4 gene and cerebral ischemia. J Neurol 2004; 251: 853—858.

80.

Netea MG , Hijmans A. , van Wissen S. et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia . Eur J Clin Invest 2004; 34: 94—99.

81.

Edfeldt K. , Bennet AM , Eriksson P. et al. Association of hypo-responsive Toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25: 1447—1453.

82.

Minoretti P. , Gazzaruso C. , Vito CD et al. Effect of the functional Toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett 2006; 391: 147—149.

83.

Mockenhaupt FP , Cramer JP , Hamann L. et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006; 103: 177—182.

84.

Rezazadeh M. , Hajilooi M. , Rafiei A. et al. TLR4 polymorphism in Iranian patients with brucellosis. J Infect 2006; 53: 206—210.

85.

Erridge C. , Stewart J. , Poxton IR Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003; 197: 1787—1791.

86.

van der Graaf C. , Kullberg BJ , Joosten L. et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005; 30: 264—268.

87.

Triantafilou K. , Triantafilou M. , Dedrick RL A CD14-independent LPS receptor cluster. Nat Immunol 2001; 2: 338—345.

88.

Lorenz E. , Jones M. , Wohlford-Lenane C. et al. Genes other than TLR4 are involved in the response to inhaled LPS. Am J Physiol 2001; 281: L1106—L1114.

89.

Pfeiffer A. , Bottcher A. , Orso E. et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol 2001; 31: 3153—3164.

90.

Newport MJ , Allen A. , Awomoyi AA et al. The Toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia . Tuberculosis (Edinb) 2004; 84: 347—352.

91.

Rittersma SZ , Kremer Hovinga JA , Koch KT et al. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and Toll-like receptor 4 gene polymorphisms. Clin Chem 2005 ; 51: 516—521.

92.

Lorenz E. , Mira JP , Cornish KL , Arbour NC , Schwartz DA A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68: 6398—6401.

93.

Schröder N. , Hermann C. , Hamann L. , Göbel U. , Hartung T. , Schumann RR High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 (TLR-2) gene detected by a novel allele specific PCR. J Mol Med 2003; 81: 368—372.

94.

von Aulock S. , Schröder N. , Traub S. et al. No influence of Toll-like receptor 2 polymorphism on lipoteichoic acid induced chemokine and anti-inflammatory responses. Infect Immun 2004; 72: 1828—1838.

95.

Schroder NW , Diterich I. , Zinke A. et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005 ; 175: 2534—2540.

96.

Gondolf KB , Mihatsch M. , Curschellas E. , Dunn JJ , Batsford SR Induction of experimental allergic arthritis with outer surface proteins of Borrelia burgdorferi. Arthritis Rheum 1994 ; 37: 1070—1077.

97.

Norgard MV , Riley BS , Richardson JA , Radolf JD Dermal inflammation elicited by synthetic analogs of Treponema pallidum and Borrelia burgdorferi lipoproteins. Infect Immun 1995; 63: 1507—1515.

98.

Ma Y. , Weis JJ Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties. Infect Immun 1993; 61: 3843—3853.

99.

Moore CE , Segal S. , Berendt AR , Hill AV , Day NP Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 2004; 11: 1194—1197.

100.

Kang TJ , Chae GT Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001; 31: 53—58.

101.

Kang TJ , Yeum CE , Kim BC , You EY , Chae GT Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 2004; 112: 674—680.

102.

Bochud PY , Hawn TR , Aderem A. A Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170: 3451—3454.

103.

Ben-Ali M. , Barbouche MR , Bousnina S. , Chabbou A. , Dellagi K. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients. Clin Diagn Lab Immunol 2004; 11: 625—626.

104.

Ogus AC , Yoldas B. , Ozdemir T. et al. The Arg753GLn polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219—223.

105.

Prebeck S. , Kirschning C. , Durr S. et al. Predominant role of Toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol 2001; 167: 3316—3323.

106.

Da Costa CU , Wantia N. , Kirschning CJ et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. Eur J Immunol 2004 ; 34: 2874—2884.

107.

Naiki Y. , Michelsen KS , Schroder NW et al. MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem 2005; 280: 29242—29249.

108.

Rupp J. , Goepel W. , Kramme E. , Jahn J. , Solbach W. , Maass M. CD14 promoter polymorphism —159C>T is associated with susceptibility to chronic Chlamydia pneumoniae infection in peripheral blood monocytes. Genes Immun 2004; 5: 435—438.

109.

Girardin SE , Boneca IG , Viala J. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869—8872.

110.

Girardin SE , Boneca IG , Carneiro LA et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003; 300: 1584—1587.

111.

Chamaillard M. , Hashimoto M. , Horie Y. et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4: 702—707.

112.

Inohara N. , Ogura Y. , Fontalba A. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509—5512.

113.

Hugot JP , Laurent-Puig P. , Gower-Rousseau C. et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821—823.

114.

Hugot JP , Chamaillard M. , Zouali H. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599—603.

115.

Ogura Y. , Bonen DK , Inohara N. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603—606.

116.

Hampe J. , Cuthbert A. , Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925—1928.

117.

Eckmann L. , Karin M.

NOD2 and Crohn's disease: loss or gain of function?

Immunity 2005; 22: 661—667.

118.

van Heel DA , Ghosh S. , Butler M. et al. Muramyl dipeptide and Toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005; 365: 1794—1796.

119.

Li J. , Moran T. , Swanson E. et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004; 13: 1715—1725.

120.

Watanabe T. , Kitani A. , Murray PJ , Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800—808.

121.

Netea MG , Kullberg BJ , de Jong DJ et al. NOD2 mediates antiinflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052—2059.

122.

Netea MG , Ferwerda G. , de Jong DJ et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 2005; 174: 6518—6523.

123.

Netea MG , Ferwerda G. , de Jong DJ et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2-but also Nod1-activating peptidoglycan agonists. J Biol Chem 2005; 280: 35859—35867.

124.

Huzarski T. , Lener M. , Domagala W. et al. The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Res Treat 2005; 89: 91—93.

125.

Papaconstantinou I. , Theodoropoulos G. , Gazouli M. et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer 2005; 114: 433—435.

126.

Lener MR , Oszutowska D. , Castaneda J. et al. Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Res Treat 2005; 89: 1—5.

127.

Hubacek JA , Stuber F. , Frohlich D. et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 29: 557—561.

128.

Hamann L. , Kumpf O. , Muller M. et al. A coding mutation within the first exon of the human MD-2 gene results in decreased lipopolysaccharide-induced signaling. Genes Immun 2004; 5: 283—288.

129.

Puel A. , Picard C. , Ku CL , Smahi A. , Casanova JL Inherited disorders of NF-kappaB-mediated immunity in man. Curr Opin Immunol 2004; 16: 34—41.

130.

Ku CL , Yang K. , Bustamante J. et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005; 203: 10—20.

131.

Courtois G. , Smahi A. , Reichenbach J. et al. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003 ; 112: 1108—1115.

132.

Picard C. , Puel A. , Bonnet M. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency . Science 2003; 299: 2076—2079.

133.

Medvedev AE , Lentschat A. , Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003; 198: 521—531.

134.

Khor CC , Chapman SJ , Vannberg FO et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39: 523—528.

135.

Imahara SD , O'Keefe GE Genetic determinants of the inflammatory response . Curr Opin Crit Care 2004; 10: 318—324.

136.

Stuber F.

Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy?

J Am Soc Nephrol 2001; 12 (Suppl 17): S60—S64.

137.

Thomas PS Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001; 79: 132—140.

138.

Vadlamani L. , Iyengar S. Tumor necrosis factor alpha polymorphism in heart failure/cardiomyopathy. Congest Heart Fail 2004; 10: 289—292.

139.

Opdal SH IL-10 gene polymorphisms in infectious disease and SIDS. FEMS Immunol Med Microbiol 2004; 42: 48—52.

140.

Lindsay JO , Hodgson HJ

The immunoregulatory cytokine interleukin-10 — a therapy for Crohn's disease?

Aliment Pharmacol Ther 2001; 15: 1709—1716.

141.

Murthy PK , Dennis VA , Lasater BL , Philipp MT Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins. Infect Immun 2000; 68: 6663—6669.

142.

Diterich I. , Harter L. , Hassler D. , Wendel A. , Hartung T. Modulation of cytokine release in ex vivo-stimulated blood from borreliosis patients. Infect Immun 2001; 69: 687—694.

143.

Giambartolomei GH , Dennis VA , Lasater BL , Murthy PK , Philipp MT Autocrine and exocrine regulation of interleukin-10 production in THP-1 cells stimulated with Borrelia burgdorferi lipoproteins . Infect Immun 2002; 70: 1881—1888.

144.

Lisinski TJ , Furie MB Interleukin-10 inhibits proinflammatory activation of endothelium in response to Borrelia burgdorferi or lipopolysaccharide but not interleukin-1beta or tumor necrosis factor alpha. J Leukoc Biol 2002; 72: 503—511.

145.

Akalin E. , Murphy B. Gene polymorphisms and transplantation. Curr Opin Immunol 2001; 13: 572—576.

146.

Hultqvist M. , Holmdahl R. Ncf1 (p47phox) polymorphism determines oxidative burst and the severity of arthritis in rats and mice. Cell Immunol 2005; 233: 97—101.

147.

Fossati G. , Bucknall RC , Edwards SW Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 2001; 31: 821—831.

148.

Hartel C. , Finas D. , Ahrens P. et al. Polymorphisms of genes involved in innate immunity: association with preterm delivery. Mol Hum Reprod 2005 ; 10: 911—915.

149.

Gazouli M. , Mantzaris G. , Kotsinas A. et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11: 681—685.

150.

Linderson Y. , Bresso F. , Buentke E. , Pettersson S. , D'Amato M. Functional interaction of CARD15/NOD2 and Crohn's disease-associated TNFalpha polymorphisms. Int J Colorectal Dis 2005; 20: 305—311.

151.

Meyer KC The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001; 128: 23—31.

152.

Krabbe KS , Pederesen M. , Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004; 39: 687—699.

153.

Caruso C. , Lio D. , Cavallone L. , Franceschi C. Aging, longevity, inflammation, and cancer. Ann NY Acad Sci 2004; 1028: 1—13.

154.

Petrovsky N. , McNair P. , Harrison LC Circadian rhythmicity of interferon-gamma production in antigen-stimulated whole blood. Chronobiologia 1994; 21: 293—300.

155.

Petrovsky N. , McNair P. , Harrison LC Diurnal rhythms of proinflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 1998; 10: 307—312.

156.

Weyerbrock A. , Timmer J. , Hohagen F. , Berger M. , Bauer J. Effects of light and chronotherapy on human circadian rhythms in delayed sleep phase syndrome: cytokines, cortisol, growth hormone, and the sleep-wake cycle. Biol Psychiatry 1996; 40: 794—797.

157.

Hohagen F. , Timmer J. , Weyerbrock A. et al. Cytokine production during sleep and wakefulness and its relationship to cortisol in healthy humans. Neuropsychobiology 1993; 28: 9—16.

158.

Zabel P. , Horst HJ , Kreiker C. , Schlaak M. Circadian rhythm of interleukin-1 production of monocytes and the influence of endogenous and exogenous glucocorticoids in man. Klin Wochenschr 1990; 68: 1217—1221.

159.

Zabel P. , Linnemann K. , Schlaak M. [Circadian rhythm in cytokines]. Immun Infekt 1993; 21 (Suppl 1): 38—40.

160.

DeRijk R. , Michelson D. , Karp B. et al. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J Clin Endocrinol Metab 1997; 82: 2182—2191.

161.

Selmaoui B. , Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci 2003; 73: 3339—3349.

162.

Hermann C. , von Aulock S. , Dehus O. et al. Endogenous cortisol determines the circadian rhythm of lipopolysaccharide- but not lipoteichoic acid-inducible cytokine release. Eur J Immunol 2006; 36: 371—379.

163.

West MA , Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002; 30: S64—S73.

164.

Porqueddu M. , Spirito R. , Parolari A. et al. Lack of association between serum immunoreactivity and Chlamydia pneumoniae detection in the human aortic wall. Circulation 2002; 106: 2647—2648.

165.

Malfertheiner P. , Sipponen P. , Naumann M. et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005; 100: 2100—2115.

166.

Moulder JW Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991; 55: 143—190.

167.

Aldous MB , Grayston JT , Wang SP , Foy HM Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966—1979. J Infect Dis 1992; 166: 646—649.

168.

Grayston JT , Campbell LA , Kuo CC et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618—625.

169.

Rottenberg ME , Gigliotti Rothfuchs AC , Gigliotti D. , Svanholm C. , Bandholtz L. , Wigzell H. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999; 162: 2829—2836.

170.

Penttila JM , Anttila M. , Varkila K. et al. Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice. Immunology 1999; 97: 490—496.

171.

Rottenberg ME , Gigliotti Rothfuchs A , Gigliotti D. et al. Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae . J Immunol 2000; 164: 4812—4818.

172.

Vuola JM , Puurula V. , Anttila M. , Makela PH , Rautonen N. Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge . Infect Immun 2000; 68: 960—964.

173.

Wang S. , Fan Y. , Brunham RC , Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection . Eur J Immunol 1999; 29: 3782—3792.

174.

Huang J. , Wang MD , Lenz S. , Gao D. , Kaltenboeck B. IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J Immunol 1999; 162: 2217—2226.

175.

Su H. , Caldwell HD CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 1995; 63: 3302—3308.

176.

Morrison RP , Caldwell HD Immunity to murine chlamydial genital infection . Infect Immun 2002; 70: 2741—2751.

177.

Morrison RP , Feilzer K. , Tumas DB Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995; 63: 4661—4668.

178.

Loomis WP , Starnbach MN Chlamydia trachomatis infection alters the development of memory CD8 + T cells. J Immunol 2006; 177: 4021—4027.

179.

Zhong G. , Fan P. , Ji H. , Dong F. , Huang Y. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 2001; 193: 935—942.

180.

Pirbhai M. , Dong F. , Zhong Y. , Pan KZ , Zhong G. The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells. J Biol Chem 2006; 281: 31495—31501.

181.

Liang FT , Yan J. , Mbow ML et al. Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect Immun 2004; 72: 5759—5767.

182.

Liang FT , Jacobs MB , Bowers LC , Philipp MT An immune evasion mechanism for spirochetal persistence in Lyme borreliosis . J Exp Med 2002; 195: 415—422.

183.

Barbour AG , Carter CJ , Sohaskey CD Surface protein variation by expression site switching in the relapsing fever agent Borrelia hermsii. Infect Immun 2000; 68: 7114—7121.

184.

Zhang JR , Hardham JM , Barbour AG , Norris SJ Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89: 275—285.

185.

Stevenson B. , El-Hage N. , Hines MA , Miller JC , Babb K. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun 2002; 70: 491—497.

186.

Kraiczy P. , Skerka C. , Zipfel PF , Brade V. Complement regulator-acquiring surface proteins of Borrelia burgdorferi: a new protein family involved in complement resistance . Wien Klin Wochenschr 2002; 114: 568—573.

187.

Lazarus JJ , Meadows MJ , Lintner RE , Wooten RM IL-10 deficiency promotes increased Borrelia burgdorferi clearance predominantly through enhanced innate immune responses . J Immunol 2006; 177: 7076—7085.

188.

Morrison DC , Ryan JL Endotoxins and disease mechanisms. Annu Rev Med 1987; 38: 417—432.

189.

Raetz CR Biochemistry of endotoxins. Annu Rev Biochem 1990; 59: 129—170.

190.

Raetz CR Bacterial lipopolysaccharides: a remarkable family of bioactive macroamphiphiles . Neidhart, F.C. : Escherichia coli and Salmonella: Cellular and molecular biology, 1996.

191.

Lehner MD , Hartung T. Endotoxin tolerance-mechanisms and beneficial effects in bacterial infection . Rev Physiol Biochem Pharmacol 2002; 144: 95—141.

192.

Caroff M. , Karibian D. , Cavaillon JM , Haeffner-Cavaillon N. Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect 2002; 4: 915—926.

193.

Erridge C. , Bennett-Guerrero E. , Poxton IR Structure and function of lipopolysaccharides. Microbes Infect 2002 ; 4: 837—851.

194.

Netea MG , van Deuren M. , Kullberg BJ , Cavaillon JM , Van der Meer JW

Does the shape of lipid A determine the interaction of LPS with Toll-like receptors?

Trends Immunol 2002; 23: 135—139.

195.

Rietschel ET , Kirikae T. , Schade UF et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8: 217—225.

196.

Rietschel ET , Brade H. , Brade L. et al. Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity . Prog Clin Biol Res 1987; 231: 25—53.

197.

Rietschel ET , Wollenberg HW , Brade H. et al. Structure and Function of the Lipid A component of lipopolysaccharides. Handbook Endotoxins 1984; 1: 187—220.

198.

Tanamoto K. , Zahringer U. , McKenzie GR et al. Biological activities of synthetic lipid A analogs: pyrogenicity, lethal toxicity, anticomplement activity, and induction of gelation of Limulus amoebocyte lysate. Infect Immun 1984; 44: 421—426.

199.

Galanos C. , Luderitz O. , Rietschel ET et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985; 148: 1—5.

200.

Loppnow H. , Brade L. , Brade H. et al. Induction of human interleukin 1 by bacterial and synthetic lipid A. Eur J Immunol 1986; 16: 1263—1267.

201.

Takeda K. , Kaisho T. , Akira S. Toll-like receptors. Annu Rev Immunol 2003 ; 21: 335—376.

202.

Lorenz E. , Patel DD , Hartung T. , Schwartz DA Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide. Infect Immun 2002; 70: 4892—4896.

203.

Erridge C. , Pridmore A. , Eley A. , Stewart J. , Poxton IR Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via Toll-like receptor 2. J Med Microbiol 2004; 53: 735—740.

204.

Werts C. , Tapping RI , Mathison JC et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001; 2: 346—352.

205.

Vogel S. , Hirschfeld MJ , Perera PY Signal integration in lipopolysaccharide (LPS)-stimulated murine macrophages . J Endotoxin Res 2001; 7: 237—241.

206.

Hirschfeld M. , Weis JJ , Toshchakov V. et al. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001; 69: 1477—1482.

207.

Ogawa T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett 1993; 332: 197—201.

208.

Weintraub A. , Zahringer U. , Wollenweber HW , Seydel U. , Rietschel ET Structural characterization of the lipid A component of Bacteroides fragilis strain NCTC 9343 lipopolysaccharide. Eur J Biochem 1989; 183: 425—431.

209.

Que-Gewirth NL , Ribeiro AA , Kalb SR et al. A methylated phosphate group and four amide-linked acyl chains in leptospira interrogans lipid A. The membrane anchor of an unusual lipopolysaccharide that activates TLR2. J Biol Chem 2004; 279: 25420—25429.

210.

Boon Hinckley M , Reynolds CM , Ribeiro AA et al. A Leptospira interrogans enzyme with similarity to yeast Ste14p that methylates the 1-phosphate group of lipid A. J Biol Chem 2005; 280: 30214—30224.

211.

Mancuso G. , Midiri A. , Biondo C. et al. Bacteroides fragilis-derived lipopolysaccharide produces cell activation and lethal toxicity via Toll-like receptor 4. Infect Immun 2005; 73: 5620—5627.

212.

Darveau RP , Pham TT , Lemley K. et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect Immun 2004; 72: 5041—5051.

213.

Nahori MA , Fournie-Amazouz E. , Que-Gewirth NS et al. Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells. J Immunol 2005; 175: 6022—6031.

214.

Dehus O. , Hartung T. , Hermann C. Endotoxin evaluation of eleven lipopolysaccharide by whole blood assay does not always correlate with Limulus amebocyte lysate assay. J Endotoxin Res 2006; 12: 171—180.

215.

Takayama K. , Qureshi N. Chemical structure of lipid A. Bacterial Endotoxic Lipopolysaccharides 1992; 1: 43—60.

216.

Loppnow H. , Libby P. , Freudenberg M. , Krauss JH , Weckesser J. , Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990; 58: 3743—3750.

217.

Qureshi N. , Takayama K. , Kurtz R. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun 1991; 59: 441—444.

218.

Golenbock DT , Hampton RY , Qureshi N. , Takayama K. , Raetz CR Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991; 266: 19490—19498.

219.

Rund S. , Lindner B. , Brade H. , Holst O. Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2. J Biol Chem 1999; 274: 16819—16824.

220.

Qureshi N. , Kaltashov I. , Walker K. et al. Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis. J Biol Chem 1997; 272: 10594—10600.

221.

Ingalls RR , Rice PA , Qureshi N. , Takayama K. , Lin JS , Golenbock DT The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995; 63: 3125—3130.

222.

Prebeck S. , Brade H. , Kirschning CJ et al. The Gram-negative bacterium Chlamydia trachomatis L2 stimulates tumor necrosis factor secretion by innate immune cells independently of its endotoxin. Microbes Infect 2003; 5: 463—470.

223.

Mueller M. , Postius S. , Thimm JG , Gueinzius K. , Muehldorfer I. , Hermann C. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines. Immunobiology 2004; 209: 599—608.

224.

Zhang X. , Glogauer M. , Zhu F. , Kim TH , Chiu B. , Inman RD Innate immunity and arthritis: neutrophil Rac and Toll-like receptor 4 expression define outcomes in infection-triggered arthritis. Arthritis Rheum 2005; 52: 1297—1304.

225.

Darville T. , O'Neill JM , Andrews Jr CW , Nagarajan UM , Stahl L. , Ojcius DM Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003; 171: 6187—6197.

226.

Lien E. , Sellati TJ , Yoshimura A. et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999; 274: 33419—33425.

227.

Hirschfeld M. , Kirschning CJ , Schwandner R. et al. Inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor 2. J Immunol 1999; 163: 2382—2386.

228.

Schroder NW , Heine H. , Alexander C. et al. Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 2004; 173: 2683—2691.

229.

Gebbia JA , Coleman JL , Benach JL Selective induction of matrix metalloproteinases by Borrelia burgdorferi via Toll-like receptor 2 in monocytes. J Infect Dis 2004; 189: 113—119.

230.

Fischer W.

Physiology of lipoteichoic acids in bacteria. Adv Microb

Physiol 1988; 29: 233—302.

231.

Gutberlet T. , Frank J. , Bradaczek H. , Fischer W. Effect of lipoteichoic acid on thermotropic membrane properties. J Bacteriol 1997; 179: 2879—2883.

232.

Neuhaus FC , Baddiley J.

A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. Microbiol Mol

Biol Rev 2003; 67: 686—723.

233.

Hufnagel M. , Huebner J. Analysis of the specific immune response against capsular polysaccharides of two patients with systemic enterococcal infections . Infection 2005; 33: 373—376.

234.

Majcherczyk PA , Rubli E. , Heumann D. , Glauser MP , Moreillon P. Teichoic acids are not required for Streptococcus pneumoniae and Staphylococcus aureus cell walls to trigger the release of tumor necrosis factor by peripheral blood monocytes. Infect Immun 2003; 71: 3707—3713.

235.

Wicken AJ , Knox KW Lipoteichoic acids: a new class of bacterial antigen. Science 1975; 187: 1161—1167.

236.

Bhakdi S. , Klonisch T. , Nuber P. , Fischer W. Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991; 59: 4614—4620.

237.

De Kimpe SJ , Kengatharan M. , Thiemermann C. , Vane JR The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 1995; 92: 10359—10363.

238.

Sugawara S. , Arakaki R. , Rikiishi H. , Takada H. Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner. Infect Immun 1999 ; 67: 1623—1632.

239.

Ohshima Y. , Ko HL , Beuth J. , Roszkowski K. , Roszkowski W. Biological properties of staphylococcal lipoteichoic acid and related macromolecules. Zentralbl Bakteriol 1990; 274: 359—365.

240.

Ohshima Y. , Beuth J. , Yassin A. , Ko HL , Pulverer G. Stimulation of human monocyte chemiluminescence by staphylococcal lipoteichoic acid. Med Microbiol Immunol 1988; 177: 115—121.

241.

Keller R. , Fischer W. , Keist R. , Bassetti S. Macrophage response to bacteria: induction of marked secretory and cellular activities by lipoteichoic acids. Infect Immun 1992; 60: 3664—3672.

242.

Fan X. , Stelter F. , Menzel R. et al. Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction. Infect Immun 1999; 67: 2964—2968.

243.

Hashimoto M. , Imamura Y. , Yasuoka J. , Kotani S. , Kusumoto S. , Suda Y. A novel cytokine-inducing glycolipid isolated from the lipoteichoic acid fraction of Enterococcus hirae ATCC 9790: a fundamental structure of the hydrophilic part. Glycoconj J 1999; 16: 213—221.

244.

Suda Y. , Tochio H. , Kawano K. et al. Cytokine-inducing glycolipids in the lipoteichoic acid fraction from Enterococcus hirae ATCC 9790. FEMS Immunol Med Microbiol 1995; 12: 97—112.

245.

Kusunoki T. , Hailman E. , Juan TS , Lichenstein HS , Wright SD Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995; 182: 1673—1682.

246.

Kusunoki T. , Wright SD Chemical characteristics of Staphylococcus aureus molecules that have CD14-dependent cell-stimulating activity. J Immunol 1996; 157: 5112—5117.

247.

Morath S. , Geyer A. , Hartung T. Structure—function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 2001; 193: 393—397.

248.

Lehner MD , Morath S. , Michelsen KS , Schumann RR , Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators . J Immunol 2001; 166: 5161—5167.

249.

Morath S. , Stadelmaier A. , Geyer A. , Schmidt RR , Hartung T. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med 2002; 195: 1635—1640.

250.

Morath S. , Geyer A. , Spreitzer I. , Hermann C. , Hartung T. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun 2002; 70: 938—944.

251.

Stoll H. , Dengjel J. , Nerz C. , Gotz F. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect Immun 2005; 73: 2411—2423.

252.

Bubeck Wardenburg J , Williams WA , Missiakas D. Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc Natl Acad Sci USA 2006; 103: 13831—13836.

253.

Hashimoto M. , Tawaratsumida K. , Kariya H. , Aoyama K. , Tamura T. , Suda Y. Lipoprotein is a predominant Toll-like receptor 2 ligand in Staphylococcus aureus cell wall components. Int Immunol 2006; 18: 355—362.

254.

Hashimoto M. , Furuyashiki M. , Kaseya R. et al. Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect Immun 2007; 75: 1926—1932.

255.

Hashimoto M. , Tawaratsumida K. , Kariya H. et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol 2006; 177: 3162—3169.

256.

von Aulock S. , Hartung T. , Hermann C. Comment on `Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus'. J Immunol 2007; 178: 2610, author reply 2610—2611.

257.

Deininger S. , Stadelmaier A. , von Aulock S. , Morath S. , Schmidt RR , Hartung T. Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J Immunol 2003; 170: 4134—4138.

258.

Morath S. , von Aulock S. , Hartung T. Structure/function relationships of lipoteichoic acids. J Endotoxin Res 2005; 11: 348—356.

259.

von Aulock S. , Morath S. , Hareng L. et al. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 2003; 208: 413—422.

260.

Hermann C. , Spreitzer I. , Schroder NW et al. Cytokine induction by purified lipoteichoic acids from various bacterial species — role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur J Immunol 2002; 32: 541—551.

261.

Albrecht I. , Tapmeier T. , Zimmermann S. , Frey M. , Heeg K. , Dalpke A. Toll-like receptors differentially induce nucleosome remodelling at the IL-12p40 promoter. EMBO Report 2004; 5: 172—177.

262.

Lotz S. , Aga E. , Wilde I. et al. Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J Leukoc Biol 2004; 75: 467—477.

263.

Opitz B. , Schroder NW , Spreitzer I. et al. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem 2001; 276: 22041—22047.

264.

Grangette C. , Nutten S. , Palumbo E. et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 2005; 102: 10321—10326.

265.

Schroder NW , Morath S. , Alexander C. et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003; 278: 15587—15594.

266.

Morr M. , Takeuchi O. , Akira S. , Simon MM , Muhlradt PF Differential recognition of structural details of bacterial lipopeptides by Toll-like receptors. Eur J Immunol 2002; 32: 3337—3347.

267.

Henneke P. , Morath S. , Uematsu S. et al. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol 2005; 174: 6449—6455.

268.

Lynch NJ , Roscher S. , Hartung T. et al. L-Ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol 2004; 172: 1198—1202.

269.

Mattsson E. , Hartung T. , Morath S. , Egesten A. Highly purified lipoteichoic acid from Staphylococcus aureus induces procoagulant activity and tissue factor expression in human monocytes but is a weak inducer in whole blood: comparison with peptidoglycan . Infect Immun 2004; 72: 4322—4326.

270.

Yipp BG , Andonegui G. , Howlett CJ et al. Profound differences in leukocyte—endothelial cell responses to lipopolysaccharide versus lipoteichoic acid. J Immunol 2002; 168: 4650—4658.

271.

Dziarski R. , Gupta D. Peptidoglycan recognition in innate immunity. J Endotoxin Res 2005; 11: 304—310.

272.

Dziarski R. , Gupta D. Staphylococcus aureus peptidoglycan is a Toll-like receptor 2 activator: a reevaluation. Infect Immun 2005; 73: 5212—5216.

273.

Travassos LH , Girardin SE , Philpott DJ et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Report 2004; 5: 1000—1006.

274.

Michie CA , Cohen J. The clinical significance of T-cell superantigens. Trends Microbiol 1998; 6: 61—65.

275.

Llewelyn M. , Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2: 156—162.

276.

Alouf JE , Muller-Alouf H. Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. Int J Med Microbiol 2003 ; 292: 429—440.

277.

Dinges MM , Orwin PM , Schlievert PM Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13: 16—34.

278.

Broll R. , Eckmann C. , Kujath P. , Bruch HP [Streptococcal toxic shock-like syndrome]. Chirurg 1998; 69: 806—812.

279.

Kusnecov AW , Goldfarb Y. Neural and behavioral responses to systemic immunologic stimuli: a consideration of bacterial T cell superantigens. Curr Pharm Res 2005; 11: 1039—1046.

280.

Hermann C. , von Aulock S. , Graf K. , Hartung T. A model of human whole blood lymphokine release for in vitro and ex vivo use. J Immunol Methods 2003; 275: 69—79.

281.

Krieg AM CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709—760.

282.

Klinman DM Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004; 4: 937—946.

283.

Verthelyi D. , Klinman DM Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003; 109: 64—71.

284.

Roberts TL , Sweet MJ , Hume DA , Stacey KJ Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioatemodified oligonucleotides. J Immunol 2005; 174: 605—608.

285.

Traub S. , von Aulock S. , Hartung T. , Hermann C. MDP and other muropeptides — direct and synergistic effects on the immune system. J Endotoxin Res 2006; 12: 69—85.

286.

Traub S. , Kubasch N. , Morath S. et al. Structural requirements of synthetic muropeptides to synergise with LPS in cytokine induction. J Biol Chem 2004; 279: 8694—8700.

287.

Diterich I. , Hartung T. Borrelia burgdorferi s.l., the infectious agent of Lyme borreliosis. Contrib Microbiol 2001; 8: 72—89.

288.

Hahn DL , Azenabor AA , Beatty WL , Byrne GI Chlamydia pneumoniae as a respiratory pathogen. Front Biosci 2002; 7: 66—76.

289.

Horn DL , Opal SM , Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand J Infect Dis Suppl 1996; 101: 9—13.

290.

Beutler B. Endotoxin antagonism: conceptual basis and therapeutic potential. Expert Opin Ther Targets 2002; 6: 147—158.

291.

Silverstein R. , Hannah P. , Johnson DC Natural adrenocorticosteroids do not restore resistance to endotoxin in the adrenalectomized mouse. Circ Shock 1993; 41: 162—165.

292.

Silverstein R. , Norimatsu M. , Morisson DC Fundamental differences during Gram-negative versus Gram-positve sepsis become apparent during bacterial challenge of D-galactosaminetreated mice. J Endotox Res 1997; 4: 173.

293.

Greenwald R. , Golub L. Biologic properties of non-antibiotic, chemically modified tetracyclines (CMTs): a structured, annotated bibliography. Curr Med Chem 2001; 8: 237—242.

294.

Boneberg EM , Hartung T. Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation . Eur J Immunol 2002; 32: 1717—1725.

295.

von Aulock S. , Hermann C. , Hartung T. Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo. J Immunol Methods 2003; 277: 53—63.